Chardan Capital Has Bullish Outlook for ABUS FY2025 Earnings

Arbutus Biopharma Co. (NASDAQ:ABUS) – Research analysts at Chardan Capital boosted their FY2025 earnings per share estimates for Arbutus Biopharma in a research note issued to investors on Monday, March 24th. Chardan Capital analyst K. Nakae now expects that the biopharmaceutical company will post earnings per share of ($0.30) for the year, up from their previous estimate of ($0.38). The consensus estimate for Arbutus Biopharma’s current full-year earnings is ($0.39) per share.

Other equities research analysts have also recently issued reports about the stock. StockNews.com cut shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, March 13th. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $5.50.

Arbutus Biopharma Stock Down 0.6 %

ABUS opened at $3.35 on Thursday. The business’s fifty day simple moving average is $3.33 and its 200 day simple moving average is $3.58. Arbutus Biopharma has a 52 week low of $2.30 and a 52 week high of $4.73. The firm has a market cap of $634.80 million, a P/E ratio of -7.79 and a beta of 1.93.

Institutional Investors Weigh In On Arbutus Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. E Fund Management Co. Ltd. purchased a new stake in shares of Arbutus Biopharma during the 4th quarter worth about $34,000. Xponance Inc. purchased a new stake in Arbutus Biopharma during the fourth quarter worth approximately $34,000. Raymond James Financial Inc. acquired a new stake in shares of Arbutus Biopharma in the fourth quarter worth $34,000. Cibc World Markets Corp purchased a new position in shares of Arbutus Biopharma in the 4th quarter valued at $45,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Arbutus Biopharma during the 4th quarter valued at $55,000. 43.79% of the stock is currently owned by institutional investors and hedge funds.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.